396 related articles for article (PubMed ID: 23659561)
1. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
[TBL] [Abstract][Full Text] [Related]
3. Comparison of hypoglycaemia episodes in people with type-2 diabetes fasting in Ramazan, treated with vildaglipton or sulphonylurea: results of the Pakistani cohort of the VIRTUE study.
Mahar SA; Hasan MI; Khan MI; Fawwad A; Hussain S; Maheshwary N; Kumar K; Siddiqi A; Khan MA
J Pak Med Assoc; 2014 Nov; 64(11):1297-302. PubMed ID: 25831650
[TBL] [Abstract][Full Text] [Related]
4. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
Göke R; Gruenberger JB; Bader G; Dworak M
Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
[TBL] [Abstract][Full Text] [Related]
5. The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study.
Hassoun AA; Al-Arouj M; Ibrahim M
Curr Med Res Opin; 2017 Jan; 33(1):161-167. PubMed ID: 27684469
[TBL] [Abstract][Full Text] [Related]
6. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.
Al-Arouj M; Hassoun AA; Medlej R; Pathan MF; Shaltout I; Chawla MS; Hristoskova S; Ditommaso S; Kadwa MY
Int J Clin Pract; 2013 Oct; 67(10):957-63. PubMed ID: 24001317
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
Hassanein M; Abdallah K; Schweizer A
Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
[TBL] [Abstract][Full Text] [Related]
8. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
[TBL] [Abstract][Full Text] [Related]
9. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Lukashevich V; Del Prato S; Araga M; Kothny W
Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
[TBL] [Abstract][Full Text] [Related]
11. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
Bosi E; Camisasca RP; Collober C; Rochotte E; Garber AJ
Diabetes Care; 2007 Apr; 30(4):890-5. PubMed ID: 17277036
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
[TBL] [Abstract][Full Text] [Related]
13. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
Scherbaum WA
Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977
[No Abstract] [Full Text] [Related]
14. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Cai L; Cai Y; Lu ZJ; Zhang Y; Liu P
J Clin Pharm Ther; 2012 Aug; 37(4):386-98. PubMed ID: 22191695
[TBL] [Abstract][Full Text] [Related]
15. Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization.
Genovese S; Tedeschi D
Adv Ther; 2013 Feb; 30(2):152-64. PubMed ID: 23430354
[TBL] [Abstract][Full Text] [Related]
16. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.
Devendra D; Gohel B; Bravis V; Hui E; Salih S; Mehar S; Hassanein M
Int J Clin Pract; 2009 Oct; 63(10):1446-50. PubMed ID: 19678856
[TBL] [Abstract][Full Text] [Related]
17. Translating science into clinical practice: focus on vildagliptin in combination with metformin.
Barnett AH
Diabetes Obes Metab; 2009 May; 11 Suppl 2():18-26. PubMed ID: 19385980
[TBL] [Abstract][Full Text] [Related]
18. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Filozof C; Gautier JF
Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
[TBL] [Abstract][Full Text] [Related]
19. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
[TBL] [Abstract][Full Text] [Related]
20. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]